Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the autoimmune gastrointestinal dysmotility industry, and what growth rate is it expected to achieve?
The autoimmune gastrointestinal dysmotility market size has grown strongly in recent years. It will grow from $1.73 billion in 2024 to $1.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing unawareness of rare diseases, rise in underdeveloped diagnostic practices, increasing cases of misdiagnosis with other gi disorders, rise in unavailability of targeted therapies, and increasing delays in research progress.
The autoimmune gastrointestinal dysmotility market size is expected to see strong growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising autoimmune disease prevalence, improving diagnostic techniques, growing healthcare expenditure, increasing rare disease registries, and better clinician education. Major trends in the forecast period include technology advancements in diagnostics, innovations in immunotherapy, development of neurogastroenterology research, research and development in motility modulators, and personalized treatment approaches.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
What are the major drivers contributing to the growth of the autoimmune gastrointestinal dysmotility market?
The rising prevalence of autoimmune disorders is expected to propel the growth of the autoimmune gastrointestinal dysmotility market going forward. Autoimmune diseases are conditions in which the body’s immune system mistakenly attacks its healthy cells, tissues, or organs instead of protecting them from infections and foreign substances. The rising prevalence of autoimmune disorders is primarily due to a combination of genetic susceptibility and environmental triggers, which together disrupt immune system regulation and increase the likelihood of the body attacking its own tissues. Autoimmune gastrointestinal dysmotility helps identify and manage underlying autoimmune disorders by revealing immune-mediated damage to the enteric nervous system, linking gastrointestinal symptoms to systemic autoimmune activity. For instance, in November 2024, according to a survey study among 73,241,305 in 2022 by the Versorgungsatlas.de, a Germany-based organization, around 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61. Therefore, the rising prevalence of autoimmune disorders is driving the growth of the autoimmune gastrointestinal dysmotility market.
Increasing Focus On Personalized Medicine Is Fueling The Market Growth Due To Advancements In Tailored Treatment Approaches For Autoimmune Conditions
The increasing focus on personalized medicine is expected to propel the growth of the autoimmune gastrointestinal dysmotility market going forward. Personalized medicine refers to a medical approach that tailor’s treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The rise of personalized medicine is primarily due to advancements in genomics, which enable precise identification of genetic variations and tailored treatments for individuals. Personalized medicine aids in the treatment of autoimmune gastrointestinal dysmotility by tailoring therapies to an individual’s genetic makeup and specific disease characteristics. This approach improves treatment efficacy and minimizes side effects, offering more targeted solutions for managing complex gastrointestinal disorders. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of autoimmune gastrointestinal dysmotility market.
What are the major market segments driving the growth of the autoimmune gastrointestinal dysmotility industry?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented –
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
View The Full Market Report:
What are the key trends shaping the autoimmune gastrointestinal dysmotility market in the forecast period?
Major companies operating in the autoimmune gastrointestinal dysmotility market are focusing on adopting strategic partnerships approach to provide digital therapy solutions for managing autoimmune gastrointestinal dysmotility conditions. Strategic partnerships enhance care for autoimmune gastrointestinal dysmotility by offering integrated, virtual-first healthcare with multidisciplinary teams, improving symptom management, access to care, and cost efficiency. For instance, in March 2022, Solera Health, a US-based digital health company, partnered with Oshi Health, a US-based virtual gastrointestinal care company and Vivante Health, a US-based digital health company. This initiative will provide advanced digital therapy solutions to support the management and treatment of autoimmune gastrointestinal dysmotility. The collaboration aims to improve patient access to specialized care and enhance overall treatment effectiveness for individuals with gastrointestinal disorders.
Who are the key market players contributing to the growth of the autoimmune gastrointestinal dysmotility industry?
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
Which regions are leading the growth of the autoimmune gastrointestinal dysmotility market globally?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Autoimmune Gastrointestinal Dysmotility Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24160&type=smp
Need Customized Data On Autoimmune Gastrointestinal Dysmotility Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
